Stock GUARD GUARD THERAPEUTICS INTERNATIONAL AB
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Guard Therapeutics International AB

Equities

GUARD

SE0021181559

Market Closed - Nasdaq Stockholm
Other stock markets
 07:52:04 02/05/2024 pm IST 		5-day change 1st Jan Change
30 SEK +2.74% Intraday chart for Guard Therapeutics International AB +1.35% -16.20%
15/04 Guard Therapeutics Receives First Regulatory Approval for the Phase 2b Study POINTER CI
21/02 Guard Therapeutics International AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Guard Therapeutics receives its first regulatory approval for the phase 2b study POINTER
AQ
Guard Therapeutics presented development strategy and new preclinical results at R&D Update
AQ
Invitation to Guard Therapeutics’ R&D Update on January 30
AQ
FDA provides positive feedback to Guard Therapeutics regarding the continued development plan for RMC-035
AQ
Guard Therapeutics presents the Nomination Committee for 2024
AQ
Guard Therapeutics presents late breaking clinical trial abstract at ASN Kidney Week 2023
AQ
Guard Therapeutics provides more information on the development strategy for RMC-035
AQ
Guard Therapeutics reports robust efficacy of RMC-035 in Phase 2 (AKITA) and advances clinical development program
AQ
Last patient visit completed in Guard Therapeutics' clinical Phase 2 study AKITA
AQ
Study results with Guard Therapeutics’ RMC-035 in kidney transplantation confirm previously positive data analysis
AQ
Guard Therapeutics provides updated information on the phase 2 study AKITA
AQ
Guard Therapeutics closes its phase 2 clinical trial AKITA following DMC recommendation
AQ
Guard Therapeutics presents positive clinical data with RMC-035 in patients undergoing kidney transplantation
AQ
Results from Guard Therapeutics' Phase 1b study in cardiac surgery published in Kidney International Reports
AQ
First US patient dosed in Guard Therapeutic’s Phase 2 AKITA study
AQ
Half of the patients dosed in the Phase 2 AKITA study
AQ
Guard Therapeutics receives patent approval for RMC-035 in China
AQ
Guard Therapeutics presents the Nomination Committee for 2023
AQ
Guard Therapeutics has decided to carry out a directed share issue of SEK 120 million, partly subject to subsequent approval by an extraordinary general meeting
AQ
Guard Therapeutics explores the conditions to carry out a directed share issue of approximately SEK 115 million
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. GUARD Stock
  4. News Guard Therapeutics International AB
  5. Press Releases